{
    "name": "Chondrodysplasia Punctata",
    "slug": "chondrodysplasia-punctata",
    "aliases": [
        "CDP",
        "Conradi-Hünermann-Happle syndrome",
        "Rhizomelic Chondrodysplasia Punctata",
        "X-linked Chondrodysplasia Punctata"
    ],
    "description": "Chondrodysplasia punctata (CDP) is a heterogeneous group of rare genetic disorders characterized by abnormalities of cartilage and bone development, leading to skeletal dysplasia. The hallmark feature is stippling (punctate calcifications) seen on X-rays, particularly around the joints, during infancy. Different forms of CDP exist, varying in severity and inheritance patterns, with some being lethal in infancy while others are milder.",
    "category": "GENETIC",
    "icdCode": "Q77.4",
    "orphaCode": "205",
    "omimCode": "215100",
    "prevalence": "1 in 100,000 births",
    "estimatedCases": 78000,
    "ageOfOnset": "Prenatal or Infancy",
    "inheritance": "AUTOSOMAL_RECESSIVE, AUTOSOMAL_DOMINANT, X_LINKED",
    "symptoms": [
        "Stippled epiphyses (punctate calcifications)",
        "Short stature",
        "Limb shortening (rhizomelia)",
        "Facial dysmorphism (e.g., flat nasal bridge, micrognathia)",
        "Cataracts",
        "Ichthyosis (scaly skin)",
        "Joint contractures",
        "Scoliosis",
        "Respiratory problems",
        "Developmental delay"
    ],
    "affectedSystems": [
        "Skeletal System",
        "Eyes",
        "Skin",
        "Respiratory System",
        "Central Nervous System"
    ],
    "prognosis": "Variable, depending on the specific type and severity. Some forms are lethal in infancy, while others allow for survival into adulthood with varying degrees of disability.",
    "lifeExpectancy": "Variable, ranging from infancy to adulthood, depending on the specific type and severity.",
    "diagnosticMethods": [
        "X-rays (to identify stippled epiphyses)",
        "Genetic testing (to identify causative mutations)",
        "Physical examination",
        "Prenatal ultrasound",
        "Biochemical testing (e.g., phytanic acid levels)"
    ],
    "treatmentOptions": [
        {
            "name": "Supportive Care",
            "type": "SUPPORTIVE",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Physical Therapy",
            "type": "THERAPY",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Occupational Therapy",
            "type": "THERAPY",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Surgery (for limb deformities or cataracts)",
            "type": "SURGERY",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Vitamin K supplementation (for VKORC1-related CDP)",
            "type": "MEDICATION",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Warfarin Management (for EBP-related CDP)",
            "type": "MEDICATION",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        }
    ],
    "researchStatus": "ACTIVE_TRIALS",
    "clinicalTrialsCount": 5,
    "keyResearchCenters": [
        "National Institutes of Health (NIH)",
        "University of California, San Francisco (UCSF)",
        "Boston Children's Hospital"
    ],
    "patientOrganizations": [
        {
            "name": "Global Genes",
            "url": "https://globalgenes.org/",
            "country": "USA"
        },
        {
            "name": "National Organization for Rare Disorders (NORD)",
            "url": "https://rarediseases.org/",
            "country": "USA"
        }
    ],
    "relatedConditions": [
        "Rhizomelic Chondrodysplasia Punctata Type 1 (RCDP1)",
        "Rhizomelic Chondrodysplasia Punctata Type 2 (RCDP2)",
        "Rhizomelic Chondrodysplasia Punctata Type 3 (RCDP3)",
        "X-linked Dominant Chondrodysplasia Punctata (CDPX1)",
        "X-linked Recessive Chondrodysplasia Punctata (CDPX2)"
    ],
    "specialistTypes": [
        "Clinical Geneticist",
        "Pediatric Orthopedist",
        "Ophthalmologist",
        "Dermatologist",
        "Developmental Pediatrician",
        "Radiologist"
    ],
    "eli5Summary": "Imagine your bones are like LEGOs, and sometimes they don't connect properly. Chondrodysplasia Punctata is when the LEGOs (bones) have tiny dots on them, making it hard for them to grow straight. This can make kids shorter and have other problems, but doctors can help them feel better.",
    "clinicalSummary": "Chondrodysplasia punctata (CDP) encompasses a group of genetically heterogeneous disorders characterized by abnormal cartilage calcification, most notably observed as stippling on radiographs of the epiphyses. The underlying pathophysiology varies depending on the specific genetic defect, affecting different metabolic pathways involved in cholesterol biosynthesis, vitamin K metabolism, or peroxisomal function. Clinical manifestations are diverse, ranging from severe, lethal forms with profound skeletal abnormalities and organ involvement to milder forms with isolated skeletal findings. Diagnosis relies on radiographic evidence of stippling, genetic testing to identify causative mutations, and biochemical assays to assess relevant metabolic pathways. Management is primarily supportive, focusing on addressing specific complications such as limb deformities, cataracts, and respiratory issues. Prognosis varies significantly depending on the underlying genetic etiology and the severity of clinical manifestations.",
    "historicalBackground": "Chondrodysplasia punctata was first described by Conradi in 1914 and later further characterized by Hünermann. The genetic heterogeneity of CDP was gradually recognized with the identification of different causative genes and inheritance patterns. The discovery of the underlying metabolic defects in various forms of CDP has led to improved diagnostic and management strategies.",
    "recentBreakthroughs": [
        {
            "year": 2022,
            "title": "Novel Gene Discoveries in CDP",
            "description": "Identification of new genes associated with atypical forms of chondrodysplasia punctata, expanding the genetic landscape of the disease.",
            "sourceUrl": null
        },
        {
            "year": 2023,
            "title": "Improved Diagnostic Techniques",
            "description": "Development of advanced imaging techniques and genetic testing methods for earlier and more accurate diagnosis of CDP subtypes.",
            "sourceUrl": null
        }
    ],
    "heroImage": null,
    "diagrams": [],
    "lastUpdated": "2024-12-01",
    "reviewedBy": "MDRPedia Medical Team",
    "sources": [
        {
            "name": "Orphanet",
            "url": "https://www.orpha.net"
        },
        {
            "name": "OMIM",
            "url": "https://www.omim.org"
        },
        {
            "name": "PubMed",
            "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
    ]
}